F S&P 500
5,076.00 +13.75 (+0.27%) F Dow Jones
38,051.00 +61.00 (+0.16%) F Nasdaq
17,728.50 +70.00 (+0.40%) E-mini Russell 2000 Index Futur
1,968.20 +6.20 (+0.32%) Petróleo
82.91 +0.22 (+0.27%) Oro
2,388.70 +0.30 (+0.01%)
G1 Therapeutics, Inc. (GTHX)
Fuera de horario:
G1 Therapeutics, Inc.
700 Park Offices Drive
Suite 200
Research Triangle Park, NC 27709
United States
919 213 9835
https://www.g1therapeutics.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 100
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. John E. Bailey Jr. | CEO, President & Director | 1.06M | N/D | 1965 |
| Mr. Mark Avagliano | Chief Business Officer | 628.54k | N/D | 1976 |
| Mr. John W. Umstead V | Chief Financial Officer | N/D | N/D | 1985 |
| Mr. Terry L. Murdock | Chief Operating Officer | 541.59k | 606.34k | 1960 |
| Mr. William C. Roberts | Vice President of Investor Relations & Corporate Communications | N/D | N/D | 1969 |
| Ms. Monica R. Thomas | Chief Legal & People Officer | N/D | N/D | N/D |
| Mr. Evan Hicks M.B.A. | Vice President of Marketing | N/D | N/D | N/D |
| Dr. Rajesh K. Malik Ch.B., M.B., M.D. | Chief Medical Officer | 596.37k | 1.48M | 1959 |
| Mr. Andrew Perry | Chief Commercial Officer | 568.6k | N/D | 1973 |
| Mr. Jeff Macdonald | Senior Director of Investor Relations & Corporate Communications | N/D | N/D | N/D |
Descripción
G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.
Gestión corporativa
La calificación ISS Governance QuickScore de G1 Therapeutics, Inc. a partir del 1 de abril de 2024 es 7. Las puntuaciones principales son Auditoría: 3; Junta: 7; Derechos del accionista: 8; Compensación: 9.
